ERBB2 and breast cancer: In comparison, the phase II NIMBUS trial evaluating nivolumab and ipilimumab in patients with metastatic HER2-negative breast cancer with high TMB showed partial response in 4 of 30 (13%) patients, although patients with higher TMB (14 Mut/Mb or higher) seemed to have better response rates (60%; ref. 36).